Karanth Shama D, Divaker Joel, Blair Marissa, Gray Jhanelle E, Hochhegger Bruno, Kobetz Erin, Machuca Tiago, Rackauskas Mindaugas, Yang Danting, Rodriguez Estelamari, Schabath Matthew B, Yoon Hyung-Suk, Braithwaite Dejana
Division of Population Health Sciences, Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA.
University of Florida Health Cancer Center, Gainesville, FL, USA.
J Thorac Dis. 2024 Oct 31;16(10):7143-7154. doi: 10.21037/jtd-24-846. Epub 2024 Oct 30.
Despite United States Preventive Services Task Force (USPSTF) recommendations, low uptake of lung cancer screening (LCS) highlights the need for measures to promote adoption. This scoping review aims to outline the global landscape of mobile low-dose computed tomography (LDCT) platforms, summarizing research and evaluating efficacy in screening at-risk populations.
We comprehensively searched Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed, Embase, Scopus, and Web of Science for articles published between 2017 and 2023. Selected studies focused on mobile LCS programs using LDCT, providing details on program location, design, sample size, age, targeted population, lung cancer detection rate, and outcomes. Only studies meeting these criteria were considered.
The search found 12 studies meeting inclusion criteria, documenting ten mobile LDCT platforms across several countries. These studies primarily evaluated platform effectiveness in screening populations at risk, particularly targeting individuals who have ever smoked, high-risk individuals, and underserved populations. Two studies compared outcomes between mobile and hospital-based screening, while 10 other studies reported outcomes from mobile LDCT platforms. In US studies, most participants in mobile LCS programs came from rural areas, were uninsured or under-insured, and included a notable number of racial/ethnic minorities. The frequency of lung cancer diagnoses ranged from 0.33% to 3%, with the majority (80%) of detected at stages I and II.
The mobile LDCT platforms emerge as a powerful solution to enhance access to LCS, especially for marginalized populations. By improving screening rates and enabling early detection, these platforms hold promise in narrowing healthcare disparities. Mobile LDCT presents a crucial opportunity to save lives and promote equity in healthcare access.
尽管美国预防服务工作组（USPSTF）提出了建议，但肺癌筛查（LCS）的低接受率凸显了采取措施促进其采用的必要性。本范围综述旨在概述移动低剂量计算机断层扫描（LDCT）平台的全球情况，总结研究并评估其在筛查高危人群中的效果。
我们全面检索了护理及相关健康文献累积索引（CINAHL）、PubMed、Embase、Scopus和Web of Science，以查找2017年至2023年期间发表的文章。所选研究聚焦于使用LDCT的移动LCS项目，提供项目地点、设计、样本量、年龄、目标人群、肺癌检测率和结果等详细信息。仅考虑符合这些标准的研究。
检索发现12项研究符合纳入标准，记录了多个国家的10个移动LDCT平台。这些研究主要评估了平台在筛查高危人群中的有效性，尤其针对曾经吸烟的个体、高危个体和服务不足的人群。两项研究比较了移动筛查和基于医院的筛查之间的结果，而其他10项研究报告了移动LDCT平台的结果。在美国的研究中，移动LCS项目的大多数参与者来自农村地区，未参保或保险不足，并且包括相当数量的少数种族/族裔。肺癌诊断频率在0.33%至3%之间，大多数（80%）在I期和II期被检测到。
移动LDCT平台成为增强LCS可及性的有力解决方案，特别是对于边缘化人群。通过提高筛查率并实现早期检测，这些平台有望缩小医疗保健差距。移动LDCT为挽救生命和促进医疗保健可及性公平提供了关键机会。
